Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.

"Be the change you wish to see in the world..." Gandhi

Our Beneficiaries

  • University of AZ Research Centers
    University of AZ Research Centers
  • “Charity is a supreme virtue, and the great channel through which the mercy of God is passed on to mankind. It is the virtue that unites men and inspires their noblest efforts.”

    — Conrad Hilton

Brain Tumor News

An international team of researchers has discovered a new mechanism that will better activate the immune system against cancer.
The mechanism allows immune cells to detect and destroy cancer cells better than before, according to the study published this month in the journal Nature.

Researchers at Memorial Sloan Kettering Cancer Center in New York have discovered that cancer cells with high numbers of faults in their DNA are more likely to respond to immune checkpoint inhibitors (ICI), a major class of immunotherapy drugs, which includes Keytruda.

Brain Tumor Diagnosis and Treatments Market Report 2018 Provides reviews of Brain Tumor Diagnosis and Treatments Industry, including Its types, application, fabricating innovation, industry chain investigation and most recent market progression.

Glioblastoma is a deadly brain cancer that grabbed headlines for claiming the lives of Sens. Edward Kennedy and John McCain. Michael Hammer, Ph.D., and a team of University of Arizona researchers have discovered that the disease could be “tricked” into sparing more of its victims.

To treat cancer in organs like the liver, doctors are able to deliver drugs via catheter directly to the tumor, but leftover drug can escape and affect healthy organs elsewhere in the body. A drug sponge developed by UC Berkeley chemical engineers could sop up the residual drug, lessening side effects.

An international consortium led by researchers at Columbia University Vagelos College of Physicians and Surgeons, set out to better understand what occurs in NF1-glioma. Researchers analyzed tumor samples from 56 patients with NF1-glioma.

View Previous News Articles - Click Here!